Antisense oligonucleotide topical therapeutic - Feldan Therapeutics
Latest Information Update: 20 Jul 2023
At a glance
- Originator Feldan Therapeutics
- Class Antisense oligonucleotides; Peptides; Skin disorder therapies
- Mechanism of Action Gene silencing
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Research Skin disorders
Most Recent Events
- 11 Jul 2023 Early research in Skin disorders in Canada (Topical) prior to July 2023 (Feldan Therapeutics pipeline, July 2023)